See every side of every news story
Published loading...Updated

NSABP B-64/ EXActDNA-003 Breast Cancer Clinical Validation Study

Summary by Rush University Medical Center
NSABP B-64/ EXActDNA-003 Breast Cancer Clinical Validation Study abernotas Fri, 03/28/2025 - 12:28 Clinical Trial EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64) Rush University Medical Center The Sponsor of this study is developing a lab test (called Oncodetec…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Rush University Medical Center broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.